With the antibiotics market seeing a recovery as the world emerges from the COVID-19 pandemic, Centrient – a leading B2B player focused on enzymatic antibiotics, next-generation statins and anti-fungals – is continuing to maintain its focus on sustainable, innovative manufacturing, including setting the standard for antimicrobial resistance discharge targets.
In an exclusive interview with Generics Bulletin, CEO Rex Clements has set out his views on the recovery of the antibiotics market and the importance of sustainability to Centrient’s business, as well as the impact of European procurement policies, the risks of reducing